Thyroid hormone (TH) is crucial for development and metabolism of many tissues. The physiological relevance and therapeutic potential of TH analogs have gained attention in the field for many years. In particular, the relevance and use of 3,3′,5-triiodothyroacetic acid (Triac, TA 3 ) has been explored over the last decades. Although TA 3 closely resembles the bioactive hormone T 3 , differences in transmembrane transport and receptor isoformspecific transcriptional activation potency exist. For these reasons, the application of TA 3 as a treatment for resistance to TH (RTH) syndromes, especially MCT8 deficiency, is topic of ongoing research. This review is a summary of all currently available literature about the formation, metabolism, action and therapeutic applications of TA 3 .
Introduction
Thyroid hormone (TH) is crucial for the development and metabolism of many tissues. Thyroid stimulating hormone (TSH) controls the production and secretion of TH by the thyroid gland, which predominantly produces the prohormone thyroxine (T 4 ) and to a lesser extent the bioactive hormone 3,3′,5-triiodothyronine (T 3 ). T 3 mainly exerts its effects through binding to its nuclear receptors (TRs) at T 3 response elements (TREs), resulting in the transcriptional regulation of TH target genes (genomic effects). The TRα1, TRβ1 and TRβ2 isoforms are T3-binding TRs isoforms (Lazar 1993 , Ortiga-Carvalho et al. 2004 ). In addition, several non-genomic effects have been ascribed to TH (Davis et al. 2011 , Lin et al. 2012 . To exert its biological function, TH has to cross the cell membrane, which requires membrane transporter proteins (Hennemann et al. 2001 and reviewed in Visser 2007 and Bernal et al. 2015 . Monocarboxylate transporter 8 (MCT8) is the most specific TH transporter and the only TH transporter associated with human disease (Dumitrescu et al. 2004 , Friesema et al. 2004 ).
The deiodinases (D1-3) importantly regulate the bioavailability of T3 in targets cells, while TH is also metabolized by glucuronidation and sulfation, which enhance biliary excretion , Burger 1986 , Visser 1996 . Other modifications of iodothyronines include decarboxylation of the alanine side chain, resulting in iodothyronamines (Scanlan et al. 2004 , Hoefig et al. 2015 , and subsequent oxidative deamination resulting in the formation of iodothyroacetic acid derivatives (Wood et al. 2009 ). Recently, potential biological actions have been ascribed to 3-iodothyronamine (3-T 1 AM) and thyronamine (T 0 AM) (reviewed in Hoefig et al. 2016) . The biological actions of 3,3′,5-triiodothyroacetic acid (Triac; TA 3 ) and 3,3′,5,5′-tetraiodothyroacetic acid (Tetrac, TA 4 ) have been more extensively described. The biological actions of TA 3 closely resemble those of T 3 , although important differences in the cellular transport mechanism and TR-isoform-specific potency exist. For these reasons, TA 3 holds therapeutic potential in the treatment of 234:2 patients with specific defects in TH signaling, such as patients harboring mutations in TRβ (resistance to thyroid hormone (RTH)-β). Likewise, the therapeutic use of TA 3 in patients lacking the MCT8 transporter (MCT8 deficiency or the Allan-Herndon-Dudley syndrome, AHDS) is subject of ongoing research.
In this review we summarize the literature from the 1950s until now regarding the biosynthesis, metabolism, action and putative therapeutic applications of TA 3 .
Kinetic properties of TA 3 in humans
TA 3 is a naturally occurring TH metabolite, with reported serum levels between 2.6 and 15.2 ng/dL (42-244 pmol/L) in healthy human subjects (Nakamura et al. 1978 , Burger et al. 1979 , Gavin et al. 1980 , whereas others reported TA 3 levels below the assay detection limit of ~4 ng/dL (64 pmol/L) (Menegay et al. 1989) . The free fraction of TA 3 in plasma is relatively low compared to T 3 , due its high affinity for plasma binding proteins, exceeding that of T 3 by 16-fold in rats (Ingbar 1960 , Gosling et al. 1976 . In humans, TA 3 particularly binds to transthyretin (TTR), whereas its binding to thyroxine binding globulin is negligible (Robbins & Rall 1955 , Christensen 1960 , Ingbar 1960 . Nevertheless, the plasma clearance rate of TA 3 considerably exceeds the clearance rate of T 3 in humans (compiled data shown in Table 1 ). The clearance rate of TA 3 in rats is more similar to that of T 3 (Table 1 ; Gosling et al. 1976 , Liang et al. 1997 . In humans, the estimated plasma half-life of TA 3 is ~6 h and, thus, is markedly shorter than the half-life of T 3 (~24 h) (Table 1) . Peak levels occur within 40 min after oral administration and higher peak levels are achieved upon intravenous administration (Menegay et al. 1989) . The intestinal absorption efficiency amounts to 50-67% and the daily TA 3 production rate (PR) to 3.2-7.8 µg/day (Burger et al. 1979 , Gavin et al. 1980 , Siegrist-Kaiser et al. 1994 ). Gavin and coworkers (Gavin et al. 1980) found a slightly higher PR in athyroid subjects on 80 µg/day LT 3 substitution (10.1 ± 0.4 µg/day). A caveat in assessing circulating TA 3 concentrations is the interference of T 3 in the TA 3 radioimmunoassay (RIA) due to high antibody cross-reactivity (up to 50%). When preceded by proper serum extraction and column chromatography methods, this can be reduced to 1-6% (Burger et al. 1979 , Gavin et al. 1980 , Menegay et al. 1989 . Since serum T 3 levels exceed those of TA 3 by about 50-fold, this leads to considerable overestimation of endogenous TA 3 levels.
Together, TA 3 is a naturally occurring TH metabolite, present in humans at ~50-fold lower concentrations than T 3 and is rapidly cleared from the circulation despite its high affinity for plasma binding proteins.
Biosynthesis of TA 3
The first evidence for in vivo TA 3 formation was provided by studies in thyroidectomized rats demonstrating the presence of 131 I-TA 3 in kidney homogenates after injection of 131 I-T3 ). These findings were confirmed by incubation of rat kidney mitochondrial Robbins & Rall (1955) , Christensen (1960) , Green & Ingbar (1961) , Oppenheimer (1974) , Burger & Vallotton (1975) , Chopra (1976) , Gavin et al. (1977 Gavin et al. ( , 1980 , Nakamura et al. (1978) , Burger et al. (1979) , Pittman et al. (1980) , , Menegay et al. (1989) , Lopresti & Dlott (1992) TA 3 42-244 40 6.5 ± 0.5 222-298 TTR 5.2 ± 1.5 Rat T 3 768 -~2 4.2-7.3 2.3-2.5 Wilkinson et al. (1959 ), Gosling et al. (1976 , Cavalieri et al. (1984) , Nguyen et al. (1993) , Liang et al. (1997) TA 3 402 -~1 3.5-9.4
Overview of kinetic properties of T3 and TA3 in humans and rats. Data are compiled from indicated references. Peak levels have been determined after oral administration. MCR, metabolic clearance rate; PR, production rate; t 1/2 , plasma half life time; TBG, thyroxine binding globulin, TTR, transthyretin.
extracts (Albright et al. 1956) , and rat kidney (Tomita et al. 1957) or brain (Tata et al. 1957) homogenates with 131 I-T 4 and 131 I-T 3 . More recent studies confirmed the in vivo formation of TA3 upon T3 injection in rats (MedinaGomez et al. 2008) . In vivo formation of TA 3 and TA 4 was demonstrated in humans after administration of 125 I-LT 4 (Braverman et al. 1970) , whereas others detected TA 3 after the administration of 125 I-TA 4 (Burger et al. 1979 , Burger 1986 ) Based on these findings it was assumed that T 3 and/or TA 4 are intermediates in the conversion of T 4 to TA 3 . The mechanism by which iodothyronines are converted to iodothyroacetic acid metabolites has not been fully elucidated. A common hypothesis involves the decarboxylation and successive oxidative deamination of the alanine side chain of iodothyronines. Recently, purified human intestinal ornithine decarboxylase (ODC) was indeed demonstrated to facilitate the decarboxylation of 3,5-T 2 to 3,5-diiodothyronamine (T 2 AM) and T 4 to 3,3′,5,5′-tetraiodothyronamine (T 4 AM) (Hoefig et al. 2015) . The involvement of aromatic l-amino acid decarboxylase (AADC, or l-DOPA decarboxylase), long regarded as the most likely candidate, has been disproven (Hoefig et al. 2012) . It remains to be studied if other decarboxylases also possess this capacity. Although, recent studies have demonstrated the presence of decarboxylated (iodo)thyronine metabolites 3-T 1 AM and T 0 AM in vivo (Scanlan et al. 2004) , other iodothyronamines have not been detected in human serum thus far.
The oxidative deamination of T 1 AM and T 3 AM to their thyroacetic acid counterparts has been demonstrated in HepG2 cells and human thyroid tissue and was reduced by iproniazide, an inhibitor of monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (Wood et al. 2009 ). It was suggested that at least one of these enzymes converts 3-T 1 AM and T 3 AM to their aldehyde intermediates, which may be substrates for the abundantly expressed aldehyde dehydrogenase (ALDH), resulting in the formation of 3-iodothyroacetic acid (3-TA 1 ) and TA 3 , respectively (Wood et al. 2009 ). Of interest, TA 3 modulates the activity of ALDH (McCarthy et al. 1968 , Mårdh et al. 1987 , Zhou & Weiner 1997 . Conversion of T 4 AM to TA 4 has not been demonstrated thus far. Although iodothyronamines are efficiently deiodinated, neither D1 nor D2 catalyzes the conversion of T 4 AM to T 3 AM (Piehl et al. 2008) . This indicates that conversion of T 4 AM to T 3 AM is not an intermediate step in the conversion of T 4 to TA 3 (Fig. 1) . Together, these studies support the hypothesis that at least some iodothyronines can be converted to their acetic acid metabolites via a thyronamine intermediate. An alternative route for the metabolism of the alanine side chain of iodothyronines involves its conversion by aminotransferase(s) to pyruvic acid, followed by decarboxylation to acetaldehyde and oxidation to acetic acid (e.g. Wilkinson 1957 ). However, the enzymes catalyzing these reactions remain to be identified.
Metabolism of TA 3
TA 3 has been shown to be metabolized via similar pathways as T 3 , i.e. stepwise deiodination, and conjugation with glucuronic acid and sulfate.
Deiodination
Early studies found that TA 3 inhibits inner ring deiodination (IRD) of T3 in rat brain microsomes (Kaplan et al. 1983) and monkey hepatocellular carcinoma cells (Sorimachi & Yasumura 1981) . Later studies demonstrated that TA 3 is efficiently deiodinated to 3,3′-diiodothyroacetic acid (3,3′-TA 2 ) by D1 and D3 (Rutgers et al. 1989a , 
Figure 1
Schematic overview of cellular formation, metabolism and action of TA 3 . Dashed lines represent processes for which the involved enzymes/ transporters have not been identified but their existence may be assumed based on theoretical grounds or experimental data. D, deiodinase; MAO, monamine oxidase; SSAO, semicarbazide-sensitive amine oxidase; ODC, ornithine decarboxylase; TK 3 , 3,3′,5-triiodothyropyruvic acid. Horn et al. 2013) . TA 3 is even a better substrate for D1 than T 3 , illustrated by a 16-fold higher Vmax/Km ratio (Rutgers et al. 1989a ). Similar to T 3 , TA 3 induced the expression and activity of D1 in rat liver and kidney (MedinaGomez et al. 2008) . Moreover, outer ring deiodination by Dio1 and Dio2 mediates the conversion of TA 4 to TA 3 (Burger et al. 1975 , Köhrle et al. 1986 , Horn et al. 2013 .
In humans, up to 60% of the administrated 131 I-TA 3 dose appears in urine as inorganic 131 I within 24 h (Green & Ingbar 1961) , suggesting that deiodination of (conjugated) TA 3 comprises an important metabolic pathway in vivo. In contrast, Flock and coworkers (Flock et al. 1962) found that only 20% of 131 I-TA 3 administered to dogs appeared as inorganic 131 I in urine within 24 h, while 3,3′-TA 2 sulfate was also detected in serum. A similar fraction of 131 I-TA 3 was excreted in urine as inorganic 131 I in rats (Wilkinson et al. 1959 , Juge-Aubry et al. 1995 .
Deiodination of TA 3 ultimately results in the formation of thyroacetic acid (TA 0 ), which is excreted in urine in humans (Chopra et al. 1988) . Given that the estimated PRs of TA 4 and TA 3 together amount to ~10 µg/day (Pittman et al. 1980 , Siegrist-Kaiser & Burger 1994 , the urinary TA 0 levels (up to ~15 µg/L) cannot be derived from deiodination of endogenous TA 4 and TA 3 alone. Based on the studies of Hoefig and coworkers (Hoefig et al. 2015) and Wood and coworkers (Wood et al. 2009 ), the metabolism of (iodo)thyronines such as 3,5-T 2 , 3-T 1 and T 0 via thyronamine intermediates to their thyroacetic acid derivatives also contributes to urinary TA 0 excretion.
Conjugation
In addition to deiodination, conjugation of TA 3 to its glucuronide (TA 3 G) and sulfate (TA 3 S) constitutes an important part of TA 3 metabolism. Incubation of rat hepatocytes with 131 I-TA 3 results in almost complete metabolism of TA 3 within 3 h, mainly to TA 3 G (50%), 131 I − (40%) and TA 3 S (<10%) (Rutgers et al. 1989b) . The formation of TA 3 G and TA 3 S increases to 60% and 16%, respectively, by blocking Dio1 with propylthiouracil (PTU), and TA 3 G levels even further increase to 80% by simultaneous inhibition of sulfation, without affecting total TA 3 metabolism (Rutgers et al. 1989b) .
Similar to sulfated iodothyronines, TA 3 S is rapidly degraded through IRD (Rutgers et al. 1989a) . The aryl sulfotransferase Sult1a1 (or phenol sulfotransferase 1 (PST1)) mediates the sulfation of TA 3 at the 4′-hydroxyl group in rats (Sekura et al. 1981) and the ubiquitously expressed (human) SULT1A1 is the most likely candidate in humans (Visser 1994) . In rats, stable ether glucuronides are formed at the phenolic hydroxyl group of TA 3 , whereas mainly labile ester glucuronides at the carboxyl group are formed in humans (Burger 1986 , Moreno et al. 1994 .
Although deiodination of TA 3 S appears to be the principal metabolic route of TA 3 in humans, TA 3 G is the major TA 3 metabolite excreted in bile , Green & Ingbar 1961 . Up to 50% of 131 I-TA 3 administered to rats is excreted within 4 h as TA 3 G in bile (Rutgers et al. 1989b) , suggesting that glucuronidation is also the main route of TA 3 metabolism in rats. Interestingly, serum TA 3 S and biliary TA 3 G and TA 3 S excretion are increased by blocking deiodination with PTU, without affecting the TA 3 clearance rate. Flock and coworkers (Flock et al. 1965 ) obtained similar results using another D1 inhibitor, butyl 4-hydroxy-3,5-diiodobenzoate (BHDB). Bilirubin glucuronosyltransferase-deficient Gunn rats show a reduction in biliary excretion of TA 3 G, accompanied by a compensatory increase of non-specified metabolites in urine (Flock et al. 1965) . Moreover, newborn sheep reveal a rapid decrease of TA 3 S plasma levels which coincides with the maturation of glucuronosyltransferase (and deiodinase) expression (Wang et al. 1986 , Wu et al. 2008 . Lastly, hepatectomized dogs show complete abolishment of TA 3 G formation and a concomitant increase in sulfate conjugates in plasma and urine, most predominantly 3′-TA 1 S and 3,3′-TA 2 S (Flock et al. 1962) .
Together, these studies suggest that deiodination and conjugation are responsible for a stable TA 3 clearance, even in case one of these pathways is not properly functioning. Importantly, since the relative contribution of these pathways differs across species, metabolic and kinetic studies in animal models should be extrapolated to different models with caution.
Cellular transport of TA 3
As for TH, the cellular entry of TA 3 is supposed to be transporter-mediated. Studies using rat anterior pituitary cells and cardiomyocytes have shown a similar time course of 125 I-TA 3 and 125 I-T 3 uptake (Everts et al. 1994 , Verhoeven et al. 2002 . Based on free hormone levels, the transport rate of TA 3 even exceeds that of T 3 (Everts et al. 1994 , Verhoeven et al. 2002 . Moreover, TA 3 competes with TH uptake in rat anterior pituitary cells and isolated hepatocytes, but not in rat cardiomyocytes (Blondeau et al. 1988 , Everts et al. 1994 , Neves et al. 2002 , Verhoeven et al. 2002 . These findings suggest that tissue-specific transporters facilitate the cellular entry 234:2 of TA 3 , some of which may work in an ATP and sodium independent manner (Everts et al. 1994) .
TA 3 transporters have not been identified yet. MCT8, MCT10 and Organic Anion Transporting Polypeptide (OATP)1C1 do not appear relevant for transport of TA 3 (Horn et al. 2013 , Groeneweg et al. 2014 . Studies in rodents suggest that the TA 3 transporter(s) are widely expressed, given the increase in TA 3 levels in many tissues after injection of TA 3 (Medina-Gomez et al. 2008 . However, the transporter(s) involved remain to be identified.
Molecular basis of TA 3 action
TA 3 binds efficiently to nuclear TRs (Oppenheimer et al. 1973 , Smith et al. 1980 , Evans et al. 1983 , Bres et al. 1986 , Luo et al. 1986 ), i.e. with a similar affinity as T 3 to TRα1 and a 3-to 6-fold higher affinity than T 3 to TRβ1 and TRβ2 (Schueler et al. 1990 , Takeda et al. 1995 , Messier & Langlois 2000 , Martínez et al. 2009 ), which may indicate relative TRβ-selective binding and action of TA 3 . This is supported by a 2-to 3-fold lower EC 50 value for TRβ1 compared to TRα1 mediated transcriptional activation by TA 3 (Martínez et al. 2009 ). The preferential binding of TA 3 to TRβ is supported by X-ray crystallography (Martínez et al. 2009 ). Although TA 3 shows a better fit in the TRα1 ligand binding cavity, its binding to TRβ is more energetically favorable. This is mainly caused by a single amino acid difference between TRα1 (Ser277) and TRβ1 (Asn331) at the ligand binding domain (LBD), leading to a relative displacement of the β-hairpin of the TRβ LBD which potentiates direct substrate contacts (Wagner et al. 2001 , Martínez et al. 2009 . Of clinical importance is the relatively high affinity of TA 3 for several TRβ mutants identified in patients with RTH-β which display reduced T 3 binding (Takeda et al. 1995 , Messier et al. 2001 .
Importantly, despite its higher affinity for TRβ than T 3 , controversy exists to what extent this leads to higher transcriptional activation levels. Messier and Langlois (2000) did not observe differences in TRβ-mediated transcriptional activation potency between T 3 and TA 3 in case of the direct repeat (DR4), the most prevalent TRE configuration in humans (Yen 2001) , whereas TA 3 was 1.5-to 2-fold more potent than T 3 in case of palindrome and inverted palindrome TREs. In contrast, Martínez and coworkers (Martínez et al. 2009) found that TA 3 was also 6-fold more potent than T 3 in activating TRβ-mediated transcription in case of DR4.
Although not studied in detail, differences in the potency of TA 3 and T 3 to dissociate or recruit co-factors may exist. It was found that TA 3 has a lower efficacy than T 3 in recruiting the steroid receptor co-activator (SRC-1) to TRα1 (Koury et al. 2009 ). Of note, most of these studies have been carried out in the absence of retinoid X receptor (RXR), which has been shown to exert a central role in modulating the sensitivity of TH-responsive genes to different TR ligands (Bogazzi et al. 1997) .
The non-genomic effects of TA 3 have been scarcely studied (Lin et al. 1998 , D'Arezzo et al. 2004 . TA 3 was found to exert a stimulatory effect on the plasma membrane integrin αvβ3 receptor, although less potently compared to T 3 (D' Arezzo et al. 2004) . Taken together, TA 3 has somewhat higher affinity and transcriptional activation potency for TRβ than TRα and, thus, may exert stronger thyromimetic effects in TRβ-expressing tissues. However, it should be realized that intracellular TA 3 levels are governed by tissue-specific transporters, deiodinases and conjugating enzymes which also impact the tissuespecific biological actions of TA 3 .
Regulation and role of TA 3
TA 3 is an important bioactive hormone in marine invertebrates. Interestingly, the TR of Branchiostoma floridae (amphioxus) is selectively activated by TA 3 and not by T 3 (Paris et al. 2008 , Wang et al. 2009 ). Nevertheless, administration of T 3 to the developing amphioxus stimulates its metamorphosis (Paris et al. 2010) , suggesting that T 3 is a precursor of the bioactive hormone TA 3 . Indeed, TA 3 is present in amphioxus and its administration promotes metamorphosis to a similar extent as administration of T 3 (Paris et al. 2008 (Paris et al. , 2010 . In addition, the non-selenodeiodinase bfDy from B. floridae specifically catalyzes the IRD of TA 4 and TA 3 but not of T 4 and T 3 (Klootwijk et al. 2011) . Also in other species, TR activation by TA 3 may differ from the human situation (Oka et al. 2013) .
Although TA 3 is a naturally occurring bioactive TH metabolite in humans, its exact biological role is unknown. In addition, little is known about factors that affect its serum and tissue concentrations. Several studies found up to 3-fold increased serum TA 4 and TA 3 levels during fasting and non-thyroidal illness (Burger et al. 1976 , Pittman et al. 1980 . It was suggested that the reduction in D1 and increase in D3 activity during these 'low T 3 states', favor the formation of rT 3 and other TH metabolites such as 234:2 TA 3 (Carlin & Carlin 1993 , Farwell 2013 . Indeed, urinary excretion of TA 3 (S) is increased during fasting and iopanoic acid (IOP) treatment (LoPresti et al. 1993 , Kaiser-Siegrist & Burger 1994 . The molecular basis for these changes is largely unclear, although the role of ODC appears to be limited, since its activity is reduced during starvation (D'Agostino et al. 1987) . It has been postulated that the increased TA 3 levels are responsible for the suppression of TSH observed under these conditions despite low serum TH levels. In addition, TA 3 potently suppresses leptin secretion by rat brown and white adipocytes, and since leptin stimulates TSH secretion this may induce a further decline in TSH levels (Medina-Gomez et al. 2004 ).
Effects of TA 3 on the hypothalamuspituitary-thyroid (HPT) axis
The first recognized effect of TA 3 was the reduction of goiter in hypothyroid rats (Pitt-Rivers 1953) . In line, TA 3 effectively restores most clinical and biochemical abnormalities in myxedematous patients , 1956 , Trotter 1955 , 1956 ). Later studies showed that TA 3 potently reduces TSH secretion and TRH-receptor expression in mouse thyrotropic pituitary tumor cells (Gershengorn et al. 1979 ) and TRH-induced TSH release from rat pituitary fragments or cells (Szabolcs et al. 1991 , Everts et al. 1994 .
In euthyroid and hypothyroid rats, a dose-dependent reduction of serum TSH levels is observed within 6 h after TA 3 administration, beginning at a dose as low as 10 µg/kg (Table 2) . From these and other studies it was estimated that 62 µg (100 nmol)/kg/day TA3 has an equal TSH-suppressive effect as 16 µg (20 nmol)/kg/day LT 4 . Interestingly, Mirell and coworkers (Mirell et al. 1989) found that TSH mRNA expression levels are unchanged 6 h after TA 3 administration, suggesting that the initial decline in serum TSH is not caused by alterations at transcriptional level, but rather points to direct inhibition of TSH secretion by TA 3 . In contrast, prolonged (>12 days) TA 3 administration to rats persistently suppressed pituitary TSH mRNA levels (Juge-Aubry et al. 1995 , Liang et al. 1997 , resulting in a dose-dependent decrease in serum T 3 and T 4 levels (Medina-Gomez et al. 2008) . Similar effects on TSH levels were found in mice treated with TA 4 , whereas no effects were observed on hypothalamic TRH mRNA expression (Horn et al. 2013) .
A dose-dependent reduction of TSH levels was observed within 6-9 h after oral administration of TA 3 to euthyroid human subjects, with a lowest dose of 350 µg (~5 µg/kg) (Burger et al. 1979 , Medeiros-Neto et al. 1980 , Menegay et al. 1989 . Similar effects were observed in hypothyroid subjects and subjects with apparent TH insensitivity (Beck-Peccoz et al. 1983, Salemla et al. 1988, and  Table 3 ). Consequently, serum T 4 , rT 3 and T 3 levels decrease (Burger et al. 1979 , Medeiros-Neto et al. 1980 , Beck-Peccoz et al. 1983 , Bracco et al. 1993 . Sustained TSH suppression was best achieved upon division of the daily TA 3 dose compared with a single morning administration, although both regimes resulted in a similar reduction of serum T 4 levels (MedeirosNeto et al. 1980 , Bracco et al. 1993 .
Taken together, TA 3 inhibits TSH production and secretion by acting at the level of the pituitary, thereby regulating thyroid activity.
Effects of TA 3 on other tissues
In addition to its potent effect on the HPT axis, TA 3 also exerts thyromimetic effects on peripheral tissues (Tables 2 and 3 ). In evaluating these effects, it should be taken into account that TA 3 reduces endogenous TH production when administrated to euthyroid subjects, which also contributes to the changes in tissue TH status. Therefore, the direct effects of TA 3 can best be studied in athyroid subjects. An overview of clinical studies with TA 3 in humans is provided in Table 4 . Table 5 provides an overview of the thyromimetic potency of TA 3 in different tissues relative to T 4 . TA 3 and LT 4 dose are expressed in μg/kg (if available) or else as total daily dose. Bone formation markers include alkaline phosphatase and osteocalcin (in case of discrepant responses of these parameters within the same study, the response of osteocalcin prevails since this is a more specific marker for bone formation). Bone resorption markers include hydroxyproline or d-pyridinoline (in case of discrepant responses the parameter with the strongest response prevails). In case TA 3 and LT 4 monotherapy are compared, tissue sensitivity is expressed as TA 3 dose/LT 4 dose ratio required to obtain a similar effect size on the given parameters. In case of comparison between LT 4 + TA 3 vs LT 4 mono-therapy, tissue sensitivity is expressed relative to the TA 3 dose/Δ LT 4 dose ratio (e.g. <(ratio) means a stronger response of the parameter to low dose LT 4 + TA 3 compared to the high dose LT 4 mono-therapy at an equal TSH-suppressive dose). Only studies in which details of >2 organ systems have been provided are included in Table 5 .
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Basal metabolic rate
Pioneering studies demonstrated that TA 3 rapidly increased oxygen consumption in rat kidney slices (Thibault & PittRivers 1955) and myeloid leukemic leucocytes (Alexander & Bisset 1958) and stimulates aerobic glycolysis in primary tumor cell cultures more potently than T 3 , T 4 or TA 4 (Heimberg et al. 1955) .
At high doses of 1000-5000 µg/kg/day, TA 3 rapidly raised the oxygen consumption in hypothyroid rats (Pitt-Rivers 1953 , Wilkinson 1959 , whereas a lower TA 3 dose of 600 µg/kg/day resulted in a more gradual stimulation (Hill et al. 1960) (Table 2) . In hypothyroid patients, TA 3 stimulates basal metabolic rate (BMR) only at doses above ~4000 µg/day (50-75 µg/kg/day) (Lerman & Pitt-Rivers 1955 , 1956 , Trotter 1955 , 1956 , De Greaff et al. 1957 . Trotter (1956) showed that the effects of 4000 µg TA 3 /day (50-65 µg/kg/day) on BMR persisted beyond 5 days after treatment cessation. In contrast, administration of 45 µg TA 3 /kg/day for up to 3 weeks to euthyroid subjects significantly reduced BMR Explanation of symbols: =, no effect; ↑, stimulatory effect; ↓, inhibitory effect; +, present. In case of =, the highest dose reported to have no effects is listed in the 4th column. In case of ↑ or ↓ the lowest dose at which the effect has been reported is listed in the 4th column. *Only the studies that corrected for cross-reactivity of TA 3 in the T 3 assay are listed. i.p., intraperitoneal; i.v., intravenous; s.c., subcutaneous; stim., TRH-stimulated. Oliver & Boyd (1957) , Boyd & Oliver (1960) , Medeiros-Neto et al. (1980) , Beck-Peccoz et al. (1988) , Lind et al. (1989) , Bracco et al. (1993) , Brenta et al. (2003) ↓ Hypo ~10 µg/kg/day; 2-3 month Lerman & Pitt-Rivers (1955 , 1956 , Trotter (1955 Trotter ( , 1956 , Rall et al. (1956) , Zondek et al. (1956 ), De Graeff et al. (1957 , Ibbertson et al. (1959) , Boyd & Oliver (1960) , Hill et al. (1960) , Lerman (1961) Trotter (1955 Trotter ( , 1956 ), Lerman & Pitt-Rivers (1956) , Rall et al. (1956) , Zondek et al. (1956 ), De Graeff et al. (1957 , Ibbertson et al. (1959) , Hill et al. (1960) , Boyd & Oliver (1960) , Lerman (1961) , Sherman et al. (1997) Protein oxidation = Eu 45 µg/kg/day; 3 week Bracco et al. (1993) (Continued) 234:2 and sleeping energy expenditure, presumably due to a reduction of endogenous TH production, whereas protein oxidation was unaffected (Bracco et al. 1993) . These parameters significantly increased in subjects treated with 2.4-4.8 µg LT 4 /kg/day (Bracco et al. 1993) . In general, TA 3 exerts similar effects on BMR at 4-to 30-fold lower doses of LT 4 and 15-to 100-fold lower doses of LT 3 (Table 5) . Importantly, the TA 3 dose required to increase BMR greatly exceeds that required for adequate TSH suppression.
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Liver
Intrahepatic TA 3 levels increase upon TA 3 infusion in rats, which is in line with the important role of the liver in TA 3 clearance (Medina-Gomez et al. 2008) . TA 3 also effectively induces the expression of T 3 -responsive genes in the liver, including Dio1, to a similar extent as T 3 (Juge-Aubry et al. 1995 , Liang et al. 1997 , Alvarez et al. 2004 , MedinaGomez et al. 2008 . No changes in serum cholesterol and lipid levels or biliary excretion were observed after treatment of euthyroid rats for 4 weeks with 200 µg TA 3 / kg/day (Van Zyl 1957 , Autissier et al. 1980 . When given at equivalent TSH-suppressive doses to euthyroid or hypothyroid patients, TA 3 induced similar increases in serum sex hormone binding globulin (SHBG) and ferritin levels as LT 4 (Bracco et al. 1993 , Sherman et al. 1997 . In contrast, Beck-Peccoz and coworkers (BeckPeccoz et al. 1988 ) and Lind and coworkers (Lind et al. 1989) did not observe any changes in serum SHBG levels upon TA 3 administration in a similar dose to mildly obese euthyroid subjects on caloric restriction. In hypothyroid subjects, TA 3 also reduced serum total and LDL cholesterol as well as apoprotein B levels, generally within 2 weeks (Table 3 ). The effect of TA 3 on HDL levels was usually less pronounced. These effects of TA 3 were generally less pronounced in euthyroid subjects as the effects of TA 3 in peripheral tissues were counter-balanced by the reduction in serum T 3 induced by TA 3 , although findings vary depending on the precise TA 3 regimen used (Oliver & Boyd 1957 , Boyd & Oliver 1960 , Medeiros-Neto et al. 1980 , Bracco et al. 1993 , Brenta et al. 2003 . Other liver parameters such as ALAT, ASAT and bilirubin were typically not affected by TA 3 (Burger et al. 1979) . Taken together, TA 3 has potent thyromimetic effects in the liver.
Heart
TA 3 is efficiently taken up by rat cardiomyocytes (MedinaGomez et al. 2008) , but is a less potent regulator of TH target genes in the heart than T 3 (Liang et al. 1997) . Nevertheless, high doses of TA 4 induce cardiac hypertrophy in rats, although less potently than T 4 (Lameloise et al. 2001) . At least part of these effects is likely mediated through TA 3 . Several rat studies have shown that high doses of TA 3 (300 µg/kg/day) administered to pregnant dams induce cardiac hypertrophy and myofibril disorganization in the offspring (Olsen et al. 1977 , Hawkey et al. 1981 . These abnormalities are less pronounced using a lower TA 3 dose (Olsen et al. 1977) , or when TA 3 is administered to the newborns (Symons et al. 1975) , and they are prevented by different β-adrenergic blocking agents with membrane stabilizing properties (Hawkey et al. 1981 , Pearce et al. 1983 , 1985 . Of note, treatment for 13-19 days with TSH-suppressive doses of TA 3 (15-50 µg/kg/day) had no effect on the heart to BW ratio or myocardial structure in adult rats (Olsen et al. 1977 , Liang et al. 1997 Overview of the effects of TA 3 in humans. Details on the dosing, follow-up time and group size of these individual studies can be found in Table 4 . Explanation of symbols: =, no effect; ↑, stimulatory effect of TA 3 ; ↓, inhibitory effect of TA 3 . In case of =, the highest dose reported to have no effects is listed in the 4th column. In case of ↑ or ↓ the lowest dose at which the effect has been reported is listed in the 4th column. *Only the studies that corrected for cross-reactivity of TA 3 in the T 3 assay are listed. BMR, basal metabolic rate; CHD, coronary heart disease; i.v., intravenous; RMR, resting metabolic rate; SEE, sleeping energy expenditure. Severe complications due to cordocentesis BMR, basal metabolic rate; BW, body weight; chol, cholesterol; eu, euthyroid; HR, heart rate; hyper, hyperthyroid; hypo, hypothyroid; myx, myxedema; TO, turn-over.
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In adult human subjects, no detrimental effects of TA 3 have been observed on cardiac structure or function (Sherman et al. 1997 , Pujol et al. 2000 . In general, no overt chronotropic effects have been noted (Tables 2  and 3 ), although incidentally episodes of palpitations and tachycardia have been reported (Trotter 1956 ). This may be attributed to its lower potency to activate TRα1 compared with T 3 (Koury et al. 2009) or its lack of nongenomic effects on Na + flux and Ca 2+ -ATPase activity in cardiomyocytes as observed with T 3 (Rudinger et al. 1984 , Huang et al. 1999 . The effects of TA 3 on the heart have not been systematically studied in humans, although several case-reports of children with RTHβ have not reported any cardiac side effects (Anzai et al. 2012) .
Adipose tissue
TH importantly regulates basal and facultative thermogenesis, mainly through induction of uncoupling protein Ucp1 in BAT (Nicholis et al. 1986 ). In rat adipocytes, TA 3 appeared more potent in upregulating Ucp1 and Dio2 expression than T 3 (Medina-Gomez et al. 2003) . Also in vivo, low doses of TA 3 resulted in upregulation of Ucp1 in BAT and induced ectopic Ucp1 expression in WAT, without affecting tissue TH levels (Medina-Gomez et al. 2008) . In addition, TA 3 inhibited leptin expression and secretion in rat brown and white adipocytes (MedinaGomez et al. 2004) .
Bone
TH stimulates bone turnover, particularly bone resorption. Prolonged hyperthyroidism results in a reduction of bone mass and bone mineral density (BMD). Similarly, in vitro studies suggest that the stimulatory effects of TA 3 on bone resorption exceed those on bone formation in fetal rat long bones, whereas the overall effects of TA 3 on fetal mouse calvarial bones were less pronounced (Kawaguchi et al. 1994a,b) .
However, daily injection of 250 µg/kg TA 3 in euthyroid rats for 40 days did not increase serum bone alkaline phosphatase (bALP) or carboxy-terminal telopeptide region of type I collagen (β-CTX), which are markers for bone formation and resorption, respectively (Alvarez et al. 2004) . In addition, the BMD of the femur did not differ significantly between TA 3 -treated and control animals (Alvarez et al. 2004) . In hypothyroid animals on the same TA 3 dose, an increase in β-CTX serum levels was observed without concomitant increase in serum bALP. However, BMD did not differ significantly between TA 3 -treated and control animals (Alvarez et al. 2004) .
In athyroid human subjects, Sherman and coworkers (Sherman et al. 1997) showed that TA 3 stimulated bone turnover more potently than LT 4 , at a similar degree of TSH suppression, as is evidenced by higher ALP and osteocalcin levels (bone formation markers) and urinary pyridinoline and deoxypyridinoline excretion (bone resorption markers). Some studies suggested that TA 3 preferentially stimulates bone formation (Mechelany et al. 1991 , Sherman & Ladenson 1992 , whereas others demonstrate a more selective stimulation of bone resorption and a decrease in BMD of the femoral neck but not of the lumbar spine (Brenta et al. 2003) .
Taken together, TA 3 stimulates bone resorption and bone formation, although the currently available data are inconclusive regarding the balance between both processes. 
Brain and neurogenesis
TA 3 regulates the expression of well-known TH target genes, including Dio2 and Dio3, in SH-SY5Y neuroblastoma cells and rat brain homogenates, and stimulates the dendritic arborization of cerebellar Purkinje cells (PCs) as efficiently as T 3 (Liang et al. 1997 , Horn et al. 2013 . TA 3 also exerts T 3 -like effects on neurogenesis in vivo. Pax-8 KO mice lack endogenous TH production and consequently have a severely impaired brain development illustrated by a strongly reduced myelination and dendritogenesis of PCs. These abnormalities are largely prevented by administration of 200 µg TA 3 /kg/day from postnatal day 1 . The stimulatory effects on myelination are in line with previous studies (Van Wynsberghe et al. 1978) . Similar effects have been found with TA 4 (Horn et al. 2013) . In addition, the administration of low TA 3 doses (30 µg TA 3 /kg/day) to WT mice resulted in a reduction of intracerebral T 3 and T 4 levels but did not alter the expression levels of some positively regulated TH-dependent genes in the striatum or cerebral cortex (Bárez-López et al. 2016) . Several preclinical studies in rodents also indicated that TA 3 may have an antidepressive effect mediated through its β-adrenergic stimulatory effects (Massol et al. 1987 (Massol et al. , 1988a .
Effects of TA 3 and TA 4 on the developing human brain are largely unknown. However, several cases have been reported where TA 3 has been administered to a pregnant woman for the treatment of fetal hypothyroidism. Cortelazzi and coworkers (Cortelazzi et al. 1999) showed that TA 3 administration (2100-2800 µg/day) between 26 and 39 weeks of gestation to a hyperthyroid pregnant woman treated with PTU effectively reduced fetal goiter size within 15 days. A similar case was reported by Nicolini and coworkers (Nicolini et al. 1996) . In addition, Asteria and coworkers (Asteria et al. 1999) reported on the use of TA 3 in the treatment of a pregnant woman with RTHβ because of suspected hypothyroidism in the fetus carrying the same heterozygous mutation in TRβ. In all three cases, the infant showed a normal neuro(psycho) logical development at 20-24 months of age. Obviously, the risks and benefits of TA 3 administration during pregnancy should be carefully weighted. Nevertheless, these studies suggest that TA 3 has T 3 -like effects on the developing human brain.
Skin
Topical application of TA 3 increases dermal thickness and prevents glucocorticoid-induced skin atrophy in mice and humans (Faergemann et al. 2002 , Yazdanparast et al. 2006a , and stimulates procollagen synthesis and keratinocyte proliferation in human skin (Yazdanparast et al. 2004 , Zhang et al. 2012 , but has no beneficial effects on plaque psoriasis (Vahlquist et al. 2004 ).
Muscle and kidney
Little is known about the effects of TA 3 in muscle and kidney. In hypothyroid rats, TA 3 is efficiently taken up in striatal muscle and kidney, where the latter is also an important site for TA 3 metabolism (Medina-Gomez et al. 2008 ). Mechelany and coworkers (Mechelany et al. 1991) have shown that TA 3 reduced serum creatine kinase levels. TA 3 also increased urinary creatine levels in hypothyroid subjects, suggesting an increase in glomerular filtration rate (Lerman & Pitt-Rivers 1956 , Rall et al. 1956 , De Graeff et al. 1957 , Ibbertson et al. 1959 .
Liver
Heart Muscle Bone General 
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Therapeutic applications of TA 3 in humans
Because of its thyromimetic properties, the use of TA 3 in the treatment of different thyroid diseases has been explored, which is summarized in Table 4 .
Myxedema
The therapeutic application of TA 3 was first studied in cases of severe hypothyroidism (myxedema). In general, TA 3 doses of 10-30 µg/kg/day improved the myxedematous appearance and restored several parameters that reflect tissue TH status, including plasma cholesterol levels, urinary creatine excretion, electrocardiographic abnormalities and body weight, whereas no effect on BMR was observed (Lerman & Pitt-Rivers 1955 , 1956 , Trotter 1955 , 1956 , De Graeff et al. 1957 , Ibbertson et al. 1959 , Boyd & Oliver 1960 . Normalization of BMR is generally observed in a dose range of 50-75 µg/kg/day (Table 4 ). In general, the effects of TA 3 occur more rapidly compared to T 3 (Zondek et al. 1956 , Ibbertson et al. 1959 . Thus, TA 3 effectively restores euthyroidism in hypothyroid patients, but is less potent than LT 4 and LT 3 . Taken together, an obvious benefit for the use of TA 3 over LT 4 in the treatment of myxedematous patients is lacking.
Lipid reduction in coronary heart disease and obesity
The observed dissociated effect of low doses TA 3 on serum cholesterol levels and BMR prompted several small studies to the lipid lowering effect of TA 3 in euthyroid subjects with coronary heart disease. However, relatively high TA 3 doses, up to 5 mg daily (~70 µg/kg/day), were needed to reduce serum cholesterol levels in these studies, with usually only transient effects (Oliver & Boyd 1957 , Boyd & Oliver 1960 ). In non-controlled studies, at doses not affecting BMR, more episodes of transient thoracic pain and increased exercise intolerance have been reported in hypothyroid and euthyroid subjects independent of the TA 3 dose, which subsided after TA 3 withdrawal (Oliver & Boyd 1957 , Ibbertson et al. 1959 , Boyd & Oliver 1960 . In contrast to these early studies, Brenta and coworkers (Brenta et al. 2003) already observed a reduction in cholesterol levels using a dose of 20 µg TA 3 /kg/day in healthy subjects.
TA 3 has also been studied as a lipid lowering drug in mildly obese euthyroid females with caloric restriction (Beck-Peccoz et al. 1988) . Despite a strong reduction in serum TSH, T 4 and T 3 levels, no significant changes were found in serum cholesterol and triglyceride levels in the TA 3 treated group compared with females on caloric restriction alone.
There is no evidence that TA 3 is suitable for the long-term control of hypercholesterolemia in euthyroid subjects with or without coronary heart disease.
TSH suppression after thyroidectomy in differentiated thyroid carcinoma
TSH-suppression therapy is initiated after total thyroidectomy in patients with differentiated thyroid carcinoma. Driven by the preferential effects of TA 3 on the HPT axis, several studies evaluated TA 3 as a TSHsuppressive therapy in such patients.
Mueller-Gartner and Scheider (1988) observed a reduction in mean basal and TRH-stimulated TSH levels in patients on LT 4 monotherapy (2.6 ± 0.7 µg/kg/day) upon addition of 500 µg TA 3 daily, while only minor side effects were reported in 4 out of 25 patients. However, neither the impact on recurrence and survival rates, nor the effects on the TH state in peripheral organs were evaluated. Pujol and coworkers (Pujol et al. 1997) reported similar findings.
Mechelany and coworkers (Mechelany et al. 1991 ) compared LT 4 monotherapy alone or in combination with TA 3 . The TA 3 dose was adjusted to achieve TSH levels <0.1 U/L, as during LT 4 monotherapy. Sherman and Ladenson (1992) performed similar studies, but adjusted the LT 4 dose in order to achieve a similar degree of TSH suppression. In both studies, patients required 40-50% less LT 4 during combination therapy to achieve equivalent or even better TSH suppression. However, markers that reflect tissue TH action showed only minor or no significant differences between both treatment regimes. These findings implicate that the thyromimetic effects of TA3, at an equal TSH-suppressive dose, are at least as potent as those of LT4 in most peripheral organs.
Sherman and coworkers (Sherman et al. 1997 ) compared TA 3 vs LT 4 monotherapy. Following a baseline period (phase I) on a TSH-suppressive dose LT 4 (2.7 µg/kg/day), patients received starting doses of 24 µg TA 3 /kg twice daily or 1.9 µg LT 4 /kg/day, which were then titrated until TSH levels were below 0.1 U/L (phase II). Subjects receiving TA 3 showed a stronger increase in serum levels of SHBG, ferritin, and bone turnover markers, and a stronger decrease in serum total and LDL cholesterol and apoprotein B over baseline levels after 2 months of treatment at the final dose (48 ± 3 µg/kg/day) compared 234:2 to the LT 4 treated group (final dose: 2.2 ± 0.1 µg/kg/day). No significant differences were observed in cardiac parameters, energy expenditure or body weight between both groups. Remarkably, upon dose-escalation subjects in the LT 4 treated group received a 10-20% lower final LT 4 dose in phase II than during phase I of the study. Moreover, it appears that it was not required to further escalate the TA 3 starting dose of 24 µg TA 3 /kg twice daily in order to obtain TSH suppression <0.1 U/L.
In conclusion, TA 3 monotherapy is an adequate TSHsuppressive therapy, while at the same time providing sufficient thyromimetic effects in the peripheral tissues. TA 3 may especially have augmented thyromimetic effects on the pituitary, liver and bone. Based on the available studies, there is no obvious benefit of using TA 3 , alone or in combination with LT 4 , as TSH-suppression therapy, unless LT 4 is not tolerated.
Goiter
Brenta and coworkers (Brenta et al. 2003) showed that TA 3 (19.6 µg/kg/day) and LT 4 (1.7 µg/kg/day) were equally effective in reducing goiter size in patients with euthyroid goiter, although the proportion of patients in whom goiter size was reduced by more than 50% was higher in the TA 3 (42%) vs LT 4 (17%) treated group (although not statistically significant), while less side effects were reported. TSH levels were adequately reduced in both groups and FT 4 levels decreased in the TA 3 treated group. Most parameters that reflect peripheral TH state, including heart rate, showed insignificant changes in both treatment arms. Nevertheless, a significant decrease in serum total and LDL cholesterol as well as femoral BMD and increased deoxypyridinoline levels were observed in the TA 3 treated patients, which suggest an increase in bone resorption.
Pujol and coworkers (Pujol et al. 1998 ) studied the effect of TA 3 and T 3 as a TSH-suppressive therapy in addition to the anti-thyroid drug carbimazole in the treatment of Graves' disease, which both significantly reduced goiter volume, but did not significantly improve remission and relapse rates of Graves' disease.
Taken together, TA 3 treatment effectively reduces goiter volume in patients with (non-)toxic diffuse and nodular goiter. Since TSH-suppressive therapy is not recommended as useful goiter-reductive treatment, neither LT 4 nor TA 3 is advised for goiter reduction.
TA 3 abuse in dietary supplements
Multiple cases have been reported over the last decades on the abuse of dietary supplements, metabolic enhancers and mesotherapies containing TA 3 . Subjects presented with clinical signs of thyrotoxicosis, while TH and TSH levels were found to be suppressed (Ferner et al. 1986 , Chow & Lam 1998 , Bauer et al. 2002 , Scally & Hodge 2003 , Chan et al. 2004 , Ma et al. 2008 , Danilovic et al. 2008 , Cohen-Lehman et al. 2011 . For this reason, the US Food and Drug Administration has repeatedly issued an official warning against the consumption of dietary supplements or metabolic enhancers containing TA 3 .
Application of TA 3 in RTH syndromes
RTH syndromes results from alteration of local TH signaling due to defective cellular entry, intracellular metabolism or receptor function. The finding that TA 3 clearly exerts thyromimetic effects but differs from T 3 in its cellular transport mechanism and affinity for mutant TRβ variants, prompted studies to explore the application of TA 3 (and TA 4 ) in RTHβ and MCT8 deficiency.
RTHβ
RTHβ is caused by mutations in TRβ and biochemically characterized by elevated serum TH levels in the context of non-suppressed TSH levels. RTHβ results in decreased T3 action in tissues that express TRβ, whereas tissues that predominantly express TRα, such as the heart and brain, are relatively thyrotoxic in response to the high serum TH levels (Refetoff et al. 1993 , Forrest et al. 1996 . In vitro studies have shown that TA 3 is able to bind and activate a subset of these mutant receptors (Takeda et al. 1995) . The effects of TA 3 treatment in RTHβ patients have been described on a case-by-case basis and are currently the most wide-spread off-label application of TA 3 . In a subgroup of RTHβ patients, TA 3 is able to decrease TSH and consequently the high serum T 4 and T 3 levels. Since the thyromimetic effects of TA 3 itself do not fully compensate the reduction in endogenous TH levels, it alleviates the thyrotoxic symptoms including tachycardia, goiter, excessive sweating and behavioral problems (BeckPeccoz et al. 1983 , Lind & Eber 1986 , Faglia et al. 1987 , Salmela et al. 1988 , Kunitake et al. 1989 , Smallridge et al. 1989 , Beck-Peccoz et al. 1990 , Aguilar Diosdado et al. 1991 Crino et al. 1992, Dulgeroff et al. 1992 , Ueda et al. 1996 , Darendeliler & Basx 1997 , Radetti et al. 1997 , CliftonBligh et al. 1998 , Persani et al. 1998 , Asteria et al. 1999 , Kong et al. 2005 , Torre et al. 2005 , Wu et al. 2006 , Gurgel et al. 2008 , Santos et al. 2008 , Guran et al. 2009 , Anzai et al. 2012 , Ferrara et al. 2012 , Ramos-Prol et al. 2013 , Stagi et al. 2014 , Chatzitomaris et al. 2015 , Xue et al. 2015 . However, some patients do not respond to TA 3 treatment, which is assumed to depend on the type or location of the mutation (Hamon et al. 1988 , Persani et al. 1998 . These reports have been reviewed in more detail in Groeneweg and coworkers (Groeneweg et al. 2017) . In order to prevent overtreatment, pre-clinical analysis of the impact of mutations on T 3 and TA 3 binding and transactivation potency may predict which patients benefit from TA 3 treatment.
MCT8 deficiency
Mutations in MCT8 result in the AHDS, which is characterized by severe intellectual and motor disability and increased serum T 3 levels (Dumitrescu et al. 2004 , Friesema et al. 2004 . Transport of TH across the BBB and into neuronal cells largely depends on MCT8. Hence mutations in MCT8 result in a hypothyroid state in the brain, compromising brain development (Matheus et al. 2015) . In contrast, tissues that rely on other transporters are exposed to the high serum T 3 levels resulting in thyrotoxic tissues. Putative therapies should aim to restore TH signaling in the brain and at the same time alleviate the thyrotoxic state in the peripheral tissues. Although combination therapy of LT 4 and PTU alleviates the peripheral thyrotoxicosis, this approach does not restore TH signaling in the brain . The ideal therapy comprises a TH analog that enters the cell independently from MCT8, but exerts similar effects as TH. As outlined in this review, TA 3 fulfills these criteria (illustrated in Fig. 2) . Indeed, several pre-clinical studies have supported the therapeutic potency of TA 3 and its less rapidly metabolized precursor TA 4 in AHDS.
Mct8 KO mice show the characteristic serum TFT pattern of AHDS (Trajkovic et al. 2007 , TrajkovicArsic et al. 2010 , which is effectively normalized by TA 4 treatment (Horn et al. 2013) . However, Mct8 KO mice lack a neurological phenotype, since Oatp1c1 is likely to function as an alternative TH transporter at the BBB in mice. Indeed, in Mct8/Oatp1c1 double KO (DKO) mouse brain development is severely disturbed and closely resembles the abnormalities observed in Pax-8 KO mice (Mayerl et al. 2014) . The abnormal brain morphology in Pax-8 KO mice is largely prevented by administration of T 3 , TA 3 (200-400 µg/kg/day) or TA 4 (400 µg/kg/day) from postnatal day 1 (Horn et al. 2013 , suggesting that TA 3 and TA 4 can replace T 3 and T 4 during brain development in mice. Such effects of TA 4 were also observed in Pax-8/Mct8 DKO mice, confirming that its transport across the BBB is MCT8-independent. Most importantly, TA 3 administration (400 µg/kg/day) from postnatal day 1-12 rescued several markers of disrupted brain development in Mct8/Oatp1c1 DKO mice, including the abnormal cerebellar Purkinje cell development and myelination . In addition, TA 3 and TA 4 ameliorate the neurodevelopmental abnormalities in zebrafish models for MCT8-deficiency (De Vrieze et al. 2014 , Zada et al. 2016 and improve cerebellar Purkinje cell development in Mct8 deficient chicken (Delbaere et al. 2017) . So far, it has not been studied in these animal models to what extent TA 3 still has positive effects on brain development once treatment is initiated at a later developmental stage. This is particularly important to predict its therapeutic potency in human AHDS patients, when initiated at a relatively advanced age.
The putative role of TA 3 as a therapy for human AHDS patients is currently under investigation in a prospective interventional cohort study, the Triac Trial (NTC02060474), primarily assessing its potency to restore the peripheral thyrotoxicosis. If TA 3 would be an effective therapy, it can be anticipated that early intervention may have effects on the neurocognitive phenotype. Although TA 3 readily crosses the placenta (Asteria et al. 1999 , Cortelazzi et al. 1999 , there are many medical Schematic representation of a T 3 target cell that relies on MCT8 for its TH uptake. The proposed working mechanism of TA 3 (and other TH analogues) in case of defective MCT8 entails cellular uptake in an MCT8-independent way, binding to the TRs and preferably degradation through similar pathways as TH, which are all fulfilled by TA 3 as outlined in this review.
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and ethical considerations before justifying prenatal administration of TA 3 to mothers who are pregnant of an AHDS child.
Concluding remarks
TA 3 is a bioactive TH metabolite that has tissue-specific thyromimetic activities (Table 5 ). Although TA 3 clearly has a potent TSH-suppressive effect, its metabolic effects on liver and bone are at least as potent. In general, higher doses of TA 3 are required to achieve equal thyromimetic effects as LT 4 (and LT 3 ), mainly due to its rapid clearance. Based on the available studies, the therapeutic benefits of TA 3 over LT 4 treatment is generally limited to primary thyroid diseases. However, TA 3 holds potential in the treatment of subsets of RTHβ patients and possibly in AHDS. Clinical studies are needed to assess if and how this 'old' molecule can have full therapeutic potential in specific RTH syndromes.
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